IBRXImmunityBio, Inc.

Nasdaq immunitybio.com


$ 8.10 $ 0.06 (0.74 %)    

Friday, 10-May-2024 15:59:55 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 8.12
$ 7.95
$ 0.00 x 0
$ 0.00 x 0
$ 7.76 - $ 8.23
$ 1.25 - $ 10.53
4,112,241
na
5.46B
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 03-15-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 09-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunitybio-completes-gmp-drug-substance-manufacturing-sufficient-for-170000-doses-of-anktiva

ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA pro...

 serum-institute-of-india-inks-large-scale-supply-deal-for-bcg-use-in-immunitybios-bladder-cancer-combo-therapy

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expa...

Core News & Articles

AAPLNVDATSLACOINBAPLTRDJTAIIBRXCVNAData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-across-all-cancer-types

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio's recently ap...

Core News & Articles

TSLASOFINVDAAAPLFSDIBRXAMDAMZNMETAAIData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 piper-sandler-maintains-neutral-on-immunitybio-raises-price-target-to-6

Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and raises the price target from $...

 whats-going-on-with-immunitybio-stock

ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd...

 immunitybio-announces-results-of-anktiva-combined-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer-schedules-meeting-to-discuss-registration-path-for-anktiva-in-lung-cancer-with-fda

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and...

 fda-approves-immunitybios-bladder-cancer-drug-stock-rallies

FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. A...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION